This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Cirrhosis Management Market

Explore FMI’s extensive analysis on the Cirrhosis Management Landscape, complete with up to date market trends and statistics

Cirrhosis Management Market by Treatment, Disease Indication, End User & Region - Forecast 2022-2032

Cirrhosis Management Market Snapshot (2022-2032)

[301 Pages Report] Valued at US$ 701.8 Million in 2022, the global market for cirrhosis management is likely to exhibit a CAGR of 3.8% during the 2022-2032 forecast period, reaching US$ 1,059 Million. The market exhibited a compounded growth rate of 3.5% from 2016-21. Expansion of the market can be attributed to the increasing incidences of liver cirrhosis due to rise in the hepatitis infections across the globe.

Data Points

Key Statistics

Expected Base Year Value (2021)

US$ 676.1 Million

Projected Market Value (2022)

US$ 701.8 Million

Anticipated Forecast Value (2032)

US$ 1,059 Million

Estimated Growth Rate (2022-2032)

3.8%

Cirrhosis is a late-stage result of liver disease and its complications. Common causes of the Cirrhosis include alcohol abuse, hepatitis and nonalcoholic fatty liver disease. Treatment and Management of Cirrhosis depends on the cause of disease and how much damage exists. Liver transplantation may be an option if one’s liver is failing, due to disease.

As per the National Center for Biotechnology Information (NCBI), liver disease claims about 2 million deaths globally, every year. Currently, Cirrhosis is the 11th most cause of death. Due to aggravating situation, players in the market are taking various initiatives to tackle the worsening condition, which will benefit the industry in the coming time.

In September 2019, Versantis raised a Series B of € 14.6 Million to develop its treatment for late-stage liver cirrhosis in a phase II trial. Post the II trial, the company announced that it will use the funds to launch a phase IIa trial of the treatment in early 2020. Such factors are expected to benefit the cirrhosis management market in the forecast period.

Increasing incidences of liver cirrhosis due to rise in the hepatitis infections across the globe is one of the major factors that is expected to accelerate the growth of the global Cirrhosis Management Market over the analysis period.

On the contrary, high cost associated with drug development is one of the major factors that is expected to hinder the growth of the Cirrhosis Management Market during the forecast period.

Customize this Report

Let us know your requirement to get
100% FREE customization

Which Are Some Prominent Drivers Spearheading Cirrhosis Management Market Growth?

Increase in the occurrence of liver cirrhosis due to rise in hepatitis infections is one of the major factors that is anticipated to boost the growth of the global liver cirrhosis management market during the forecast period.

The rise in number of people suffering from liver cirrhosis can be attributed to rapidly changing lifestyles such as increase in alcohol consumption and unbalanced diet. Hence, rise in prevalence of the disease is projected to fuel the growth of the global market during the forecast period.

According to the National Center for Biotechnology Information (NCBI), around 2 billion people consume alcohol worldwide and upwards of 75 million are diagnosed with alcohol-use disorders and are at risk of alcohol-associated liver disease. Nearly 2 billion adults are obese or overweight and over 400 million have diabetes; both of which are risk factors for non-alcoholic fatty liver disease and hepatocellular carcinoma.

Increase in awareness programs and rise in research & development investment for the development of new drug molecules are expected to augment the global liver cirrhosis management market in the forthcoming years. In addition, rise in government driven initiatives in the field of liver cirrhosis treatment is another factor that is expected to propel the global market in the near future.

According to WHO, alcohol consumption is expected to cause 20% to 50% of liver cirrhosis cases. Also, the increasing obese populace is expected to grow the risk of non-alcoholic fatty liver disease caused due to build-up of fat in the liver. Other vital factors contributing to the market growth include increased R&D, growing public awareness, and expanding geriatric population.

The increasing initiative of players to launch innovative tools is projected to be an effective factor in developing the market. For instance, in March 2022, Echosens, a high-tech company offering the FibroScan ® portfolio of solutions, announced the launch of FibroScan GO, a cost-effective tool for screening lover health and improving liver health management at the point of care for primary care practices. Attributed to such factors, the market is anticipated to grow significantly in the forecast period.

What Are The Challenges Faced By The Cirrhosis Management Industry?

Stringent regulatory approvals and delayed approvals for novel drugs and vaccines is one of the major factors that is anticipated to impede the growth of the Cirrhosis Management Market during the forecast period. Also, side effects associated with products (fever, depression, and fatigue) is another vital factor that is expected to hamper the market growth in the coming time.

Moreover, high cost associated with drug development is also a major factor that is expected to limit the growth of the Cirrhosis Management Market over the analysis period. However, ongoing research studies and clinical trials for the treatment of liver disease are expected to act as a significant counter to the hampering causes and propel market growth in the coming time.

For instance, in March 2022, Siemens Healthineers launched Enhanced Liver Fibrosis (ELF) Test in the U.S. It provides clinical access to the minimally invasive prognostic tool. Thus, the market is likely to expand significantly in the coming time.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Why Is North America Emerging As An Opportunistic Cirrhosis Management Market?

In terms of regional platform, North America holds the largest market share in Cirrhosis Management market. The region is expected to surge at over 33.9% share in 2022. Developed nations like the U.S, Canada, and others are expected to make the maximum contribution to strengthen the growth of the Cirrhosis Management Market. Domination of the region can be attributed to the presence of major players like Astellas Pharma Inc., Mylan, AbbVie Inc., Merck & Co., Inc., and others.

Ongoing development in the field is anticipated to offer significant results to the market. For instance, in December 2019, Gilead Sciences, Inc. announced topline results from the 48-week, Phase 2 ATLAS study of combination and monotherapy investigational treatments for advanced fibrosis due to Nonalcoholic Steatohepatitis (NASH).

The study resulted in the improvement of various measures of fibrosis and liver injury with investigational firsocost at and cilofexor. Attributed to such factors, the market in North America is expected to develop significantly in the forecast period.

Moreover, favorable reimbursement scenario, increase in R&D investments in pharmaceutical companies & research institutes for new drug development, and the presence of major players in the region are some major factors that are expected to fuel the market growth during the forecast period.

How Is Europe Contributing To Growth Of The Cirrhosis Management Market?

According to Future Market Insights, Europe is expected to hold significant growth opportunities for Cirrhosis Management, and is expected to reach at a share of 27.4% in 2022.

According to the WHO, about 1.8% of all deaths in Europe are caused due to liver cirrhosis. Continuous efforts taken by the players in the market are likely to provide a significant boost to the market growth in the coming time. For instance, in March 2021, A-Tango Consortium, a five-year project that receives funding from European Union’s Horizon 2020, was launched.

A-Tango Consortium will perform Phase II clinical studies of an innovative therapeutic strategy that targets inflammation and improves liver regeneration, the novel therapy is called “G-TAK”. Owing to such innovations in the region, the European market is anticipated to augment significantly in the forecast period.

Europe is likely to be the second largest market for liver cirrhosis treatment during the forecast period, owing to rise in awareness about new treatment options and developed regulatory framework in the region.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Where Does Asia-Pacific Region Stand In The Cirrhosis Management Market?

According to Future Market Insights, Asia-Pacific is expected to grow with lucrative growth opportunities for Cirrhosis Management Market, and is expected to reach at a significant share of 22.2% in 2022.

Asia-Pacific is anticipated to witness notable growth, owing to rise in R&D activities, surge in liver diseases, unmet medical demands, and increase in investments in the healthcare sector in the region.

Moreover, increase in consumption of alcohol, unhealthy lifestyle leading to obesity & weight gain, presence of key players, and rise healthcare expenditure in the region are some of the major factors that are anticipated to augment the growth of the Cirrhosis Management Market over the analysis period.

In addition, the rise in prevalence of liver diseases and improving health care infrastructure are other factors propelling the market growth in the region.

How Is Middle East & Africa Contributing To Growth Of The Cirrhosis Management Market?

According to Future Market Insights, Middle East & Africa is expected to provide significant growth opportunities for Cirrhosis Management Market, and is expected to reach at a share of 11.9% in 2022.

The Middle East & Africa is expected to have significant growth in the Cirrhosis Management Market during the forecast period. The rising patient population suffering from liver cirrhosis is one of the major factors that is anticipated to escalate the market growth in the region.

The MEA is projected to have lucrative growth opportunities, attributed to the rapidly developing healthcare amenities among Saudi Arabia, Oman, and Qatar. Over 200,000 deaths took place in Sub-Saharan Africa due to liver diseases resulting in liver cirrhosis. More than 80% of the Africa’s liver disease burden is due to endemic blood-borne virus infections like HIV, hepatitis B, and hepatitis C.

Additionally, the market Middle East & Africa is anticipated to expand at a steady pace, attributed to the presence of rapidly developing economies and evolving healthcare infrastructure in these regions.

Role Of Start-Ups In Cirrhosis Management Market

There are many prominent market players in the Cirrhosis Management Market such as Galea Therapeutics, Akero Therapeutics, Inorbit Therapeutics, Ochre Bio, Ezra, Jetra Therapeutics, Moderna Therapeutics, Translate Bio, Promethera Biosciences, and AgomAb Therapeutics, among others, which are working hand-in-hand to provide the best-in-class Cirrhosis Management for enhancing the global arena.

However, there are many global start-ups in the Cirrhosis Management Market, that are stepping forward in matching the requirements of the Cirrhosis Management domain.

  • Founded in 2017, Akero Therapeutics is a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need. The company aims to advance its lead program efruxifermin (EFX), to provide a powerful new treatment for patients with NASH, a disease for which there are currently no marketed therapies.

Market Competition

Some of the key participants present in the global Cirrhosis Management market include Theravance Biopharma R&D, Alliancells Bioscience Corporation Limited, B. Braun Medical Inc., Conatus Pharmaceuticals Inc., Merck Sharp & Dohme Corp., Stempeutics Research Pvt Ltd, Epic Research & Diagnostics, Inc., Inc., and NovaShunt AG among others.

Attributed to the presence of such high number of participants, the market is highly competitive. While global players such as Theravance Biopharma R&D, Alliancells Bioscience Corporation Limited, and B. Braun Medical Inc., account for a considerable market size, several regional level players are also operating across key growth regions, particularly in North America.

Recent Key Developments In The Market Include

  • In February 2021, B.Braun Medical Inc., an eminent in infusion therapy and pain management, announced that it received approval from the U.S FDA for the first and only Acetaminophen Injection available in various doses. Acetaminophen Injection contains acetaminophen, which has been associated with cases of acute liver failure, resulting in liver transplant, and death.
  • In September 2021, Merck (MSD) announced that its antibody Keytruda met the primary endpoint of overall survival (OS) in the Phase III KEYNOTE-394 clinical trial in Asian patients with advanced hepatocellular carcinoma (HCC), the most common form of primary liver cancer.

Report Scope

Report Attribute

Details

Growth Rate

3.8% CAGR from 2022 to 2032

Market Value in 2022

US$ 701.8 Million

Market Value in 2032

US$ 1,059 Million

Base Year for Estimation

2021

Historical Data

2016-2021

Forecast Period

2022-2032

Quantitative Units

US$ Million for Value

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking,

Competitive Landscape, Growth Factors, Trends and

Pricing Analysis

Segments Covered

  • Treatment
  • Disease Indication
  • End User
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • Malaysia
  • Singapore
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel

Key Companies Profiled

Customization Scope

Available upon Request

Key Segments Profiled In The Cirrhosis Management Industry Survey

Cirrhosis Management Market by Treatment:

  • Cirrhosis Management for Treating Cirrhosis Causes
  • Cirrhosis Management via Antiviral Medications for Hepatitis B & C
  • Cirrhosis Management via Corticosteroids
  • Cirrhosis Management via Symptomatic Treatment
  • Cirrhosis Management via Analgesics
  • Cirrhosis Management via Treatment of Portal Hypertension (Beta-Blockers, Nitrates)
  • Cirrhosis Management via Treatment of Edema and Ascites (Diuretics, Antibiotics)
  • Cirrhosis Treatment to Avoid Complications
  • Cirrhosis Management via Banding Procedures/Band Ligation of Varics
  • Cirrhosis Management via Dialysis
  • Cirrhosis Management via Treatment of Osteoporosis
  • Cirrhosis Management via Vaccination for Flu and Other Complications
  • Cirrhosis Management via Liver Transplantation

Cirrhosis Management Market by Disease Indication:

  • Alcoholic Liver Cirrhosis Management
  • Non-Alcoholic Liver Cirrhosis Management

Cirrhosis Management Market by End User:

  • Cirrhosis Management in Hospitals
  • Cirrhosis Management in Ambulatory Surgical Centers
  • Cirrhosis Management in Research Institutes
  • Cirrhosis Management in Dialysis Centers
  • Cirrhosis Management in Clinics
  • Cirrhosis Management in Other Settings

Cirrhosis Management Market by Region:

  • North America Cirrhosis Management Market
  • Latin America Cirrhosis Management Market
  • Europe Cirrhosis Management Market
  • Asia Pacific Cirrhosis Management Market
  • Middle East & African Cirrhosis Management Market

Frequently Asked Questions

FMI projects the global Cirrhosis Management market to expand at a 3.8% value CAGR by 2032

North America is expected to be the most opportunistic Cirrhosis Management market, expanding at a 33.9% market share

Theravance Biopharma R&D, Alliancells Bioscience Corporation Limited, and B. Braun Medical Inc are some prominent Cirrhosis Management players

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Cirrhosis Management Market Analysis 2016-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2016-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Cirrhosis Management Market Analysis 2016-2021 and Forecast 2022-2032, By Treatment

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Treatment, 2016-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment, 2022-2032

        5.3.1. Treating Cirrhosis Causes

        5.3.2. Antiviral Medications for Hepatitis B & C

        5.3.3. Corticosteroids

        5.3.4. Symptomatic Treatment

        5.3.5. Analgesics

        5.3.6. Treatment of Portal Hypertension

        5.3.7. Treatment of Edema and Ascites

        5.3.8. Treatment to Avoid Complications

        5.3.9. Banding Procedures/Band Ligation of Varics

        5.3.10. Dialysis

        5.3.11. Treatment of Osteoporosis

        5.3.12. Vaccination for Flu

    5.4. Y-o-Y Growth Trend Analysis By Treatment, 2016-2021

    5.5. Absolute $ Opportunity Analysis By Treatment, 2022-2032

6. Global Cirrhosis Management Market Analysis 2016-2021 and Forecast 2022-2032, By Disease Indication

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Disease Indication, 2016-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease Indication, 2022-2032

        6.3.1. Alcoholic Liver Cirrhosis

        6.3.2. Non-alcoholic Liver Cirrhosis

    6.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2016-2021

    6.5. Absolute $ Opportunity Analysis By Disease Indication, 2022-2032

7. Global Cirrhosis Management Market Analysis 2016-2021 and Forecast 2022-2032, By End User

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2016-2021

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032

        7.3.1. Hospitals

        7.3.2. Ambulatory Surgical Centers

        7.3.3. Research Institutes

        7.3.4. Dialysis Centers

        7.3.5. Clinics

        7.3.6. Others

    7.4. Y-o-Y Growth Trend Analysis By End User, 2016-2021

    7.5. Absolute $ Opportunity Analysis By End User, 2022-2032

8. Global Cirrhosis Management Market Analysis 2016-2021 and Forecast 2022-2032, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2016-2021

    8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Cirrhosis Management Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. U.S.

            9.2.1.2. Canada

        9.2.2. By Treatment

        9.2.3. By Disease Indication

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Treatment

        9.3.3. By Disease Indication

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America Cirrhosis Management Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Treatment

        10.2.3. By Disease Indication

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment

        10.3.3. By Disease Indication

        10.3.4. By End User

    10.4. Key Takeaways

11. Europe Cirrhosis Management Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. U.K.

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Treatment

        11.2.3. By Disease Indication

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment

        11.3.3. By Disease Indication

        11.3.4. By End User

    11.4. Key Takeaways

12. Asia Pacific Cirrhosis Management Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Malaysia

            12.2.1.5. Singapore

            12.2.1.6. Australia

            12.2.1.7. New Zealand

            12.2.1.8. Rest of APAC

        12.2.2. By Treatment

        12.2.3. By Disease Indication

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment

        12.3.3. By Disease Indication

        12.3.4. By End User

    12.4. Key Takeaways

13. MEA Cirrhosis Management Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Treatment

        13.2.3. By Disease Indication

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Treatment

        13.3.3. By Disease Indication

        13.3.4. By End User

    13.4. Key Takeaways

14. Key Countries Cirrhosis Management Market Analysis

    14.1. U.S.

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2021

            14.1.2.1. By Treatment

            14.1.2.2. By Disease Indication

            14.1.2.3. By End User

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2021

            14.2.2.1. By Treatment

            14.2.2.2. By Disease Indication

            14.2.2.3. By End User

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2021

            14.3.2.1. By Treatment

            14.3.2.2. By Disease Indication

            14.3.2.3. By End User

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2021

            14.4.2.1. By Treatment

            14.4.2.2. By Disease Indication

            14.4.2.3. By End User

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2021

            14.5.2.1. By Treatment

            14.5.2.2. By Disease Indication

            14.5.2.3. By End User

    14.6. U.K.

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2021

            14.6.2.1. By Treatment

            14.6.2.2. By Disease Indication

            14.6.2.3. By End User

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2021

            14.7.2.1. By Treatment

            14.7.2.2. By Disease Indication

            14.7.2.3. By End User

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2021

            14.8.2.1. By Treatment

            14.8.2.2. By Disease Indication

            14.8.2.3. By End User

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2021

            14.9.2.1. By Treatment

            14.9.2.2. By Disease Indication

            14.9.2.3. By End User

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2021

            14.10.2.1. By Treatment

            14.10.2.2. By Disease Indication

            14.10.2.3. By End User

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2021

            14.11.2.1. By Treatment

            14.11.2.2. By Disease Indication

            14.11.2.3. By End User

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2021

            14.12.2.1. By Treatment

            14.12.2.2. By Disease Indication

            14.12.2.3. By End User

    14.13. Malaysia

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2021

            14.13.2.1. By Treatment

            14.13.2.2. By Disease Indication

            14.13.2.3. By End User

    14.14. Singapore

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2021

            14.14.2.1. By Treatment

            14.14.2.2. By Disease Indication

            14.14.2.3. By End User

    14.15. Australia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2021

            14.15.2.1. By Treatment

            14.15.2.2. By Disease Indication

            14.15.2.3. By End User

    14.16. New Zealand

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2021

            14.16.2.1. By Treatment

            14.16.2.2. By Disease Indication

            14.16.2.3. By End User

    14.17. GCC Countries

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2021

            14.17.2.1. By Treatment

            14.17.2.2. By Disease Indication

            14.17.2.3. By End User

    14.18. South Africa

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2021

            14.18.2.1. By Treatment

            14.18.2.2. By Disease Indication

            14.18.2.3. By End User

    14.19. Israel

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2021

            14.19.2.1. By Treatment

            14.19.2.2. By Disease Indication

            14.19.2.3. By End User

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Treatment

        15.3.3. By Disease Indication

        15.3.4. By End User

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. B. Braun Medical Inc.

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Alliancells Bioscience Corporation Limited

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Histogen, Inc.

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Stempeutics Research Pvt Ltd

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Merck Sharp & Dohme Corp.

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Epic Research & Diagnostics, Inc.

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Theravance Biopharma R&D, Inc.

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Sequana Medical AG

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Cirrhosis Management Market Value (US$ Mn) Forecast by Region, 2016-2032

Table 2: Global Cirrhosis Management Market Value (US$ Mn) Forecast by Treatment, 2016-2032

Table 3: Global Cirrhosis Management Market Value (US$ Mn) Forecast by Disease Indication, 2016-2032

Table 4: Global Cirrhosis Management Market Value (US$ Mn) Forecast by End User, 2016-2032

Table 5: North America Cirrhosis Management Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 6: North America Cirrhosis Management Market Value (US$ Mn) Forecast by Treatment, 2016-2032

Table 7: North America Cirrhosis Management Market Value (US$ Mn) Forecast by Disease Indication, 2016-2032

Table 8: North America Cirrhosis Management Market Value (US$ Mn) Forecast by End User, 2016-2032

Table 9: Latin America Cirrhosis Management Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 10: Latin America Cirrhosis Management Market Value (US$ Mn) Forecast by Treatment, 2016-2032

Table 11: Latin America Cirrhosis Management Market Value (US$ Mn) Forecast by Disease Indication, 2016-2032

Table 12: Latin America Cirrhosis Management Market Value (US$ Mn) Forecast by End User, 2016-2032

Table 13: Europe Cirrhosis Management Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 14: Europe Cirrhosis Management Market Value (US$ Mn) Forecast by Treatment, 2016-2032

Table 15: Europe Cirrhosis Management Market Value (US$ Mn) Forecast by Disease Indication, 2016-2032

Table 16: Europe Cirrhosis Management Market Value (US$ Mn) Forecast by End User, 2016-2032

Table 17: Asia Pacific Cirrhosis Management Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 18: Asia Pacific Cirrhosis Management Market Value (US$ Mn) Forecast by Treatment, 2016-2032

Table 19: Asia Pacific Cirrhosis Management Market Value (US$ Mn) Forecast by Disease Indication, 2016-2032

Table 20: Asia Pacific Cirrhosis Management Market Value (US$ Mn) Forecast by End User, 2016-2032

Table 21: MEA Cirrhosis Management Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 22: MEA Cirrhosis Management Market Value (US$ Mn) Forecast by Treatment, 2016-2032

Table 23: MEA Cirrhosis Management Market Value (US$ Mn) Forecast by Disease Indication, 2016-2032

Table 24: MEA Cirrhosis Management Market Value (US$ Mn) Forecast by End User, 2016-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Cirrhosis Management Market Value (US$ Mn) by Treatment, 2022-2032

Figure 2: Global Cirrhosis Management Market Value (US$ Mn) by Disease Indication, 2022-2032

Figure 3: Global Cirrhosis Management Market Value (US$ Mn) by End User, 2022-2032

Figure 4: Global Cirrhosis Management Market Value (US$ Mn) by Region, 2022-2032

Figure 5: Global Cirrhosis Management Market Value (US$ Mn) Analysis by Region, 2016-2032

Figure 6: Global Cirrhosis Management Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 7: Global Cirrhosis Management Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 8: Global Cirrhosis Management Market Value (US$ Mn) Analysis by Treatment, 2016-2032

Figure 9: Global Cirrhosis Management Market Value Share (%) and BPS Analysis by Treatment, 2022-2032

Figure 10: Global Cirrhosis Management Market Y-o-Y Growth (%) Projections by Treatment, 2022-2032

Figure 11: Global Cirrhosis Management Market Value (US$ Mn) Analysis by Disease Indication, 2016-2032

Figure 12: Global Cirrhosis Management Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032

Figure 13: Global Cirrhosis Management Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032

Figure 14: Global Cirrhosis Management Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 15: Global Cirrhosis Management Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 16: Global Cirrhosis Management Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 17: Global Cirrhosis Management Market Attractiveness by Treatment, 2022-2032

Figure 18: Global Cirrhosis Management Market Attractiveness by Disease Indication, 2022-2032

Figure 19: Global Cirrhosis Management Market Attractiveness by End User, 2022-2032

Figure 20: Global Cirrhosis Management Market Attractiveness by Region, 2022-2032

Figure 21: North America Cirrhosis Management Market Value (US$ Mn) by Treatment, 2022-2032

Figure 22: North America Cirrhosis Management Market Value (US$ Mn) by Disease Indication, 2022-2032

Figure 23: North America Cirrhosis Management Market Value (US$ Mn) by End User, 2022-2032

Figure 24: North America Cirrhosis Management Market Value (US$ Mn) by Country, 2022-2032

Figure 25: North America Cirrhosis Management Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 26: North America Cirrhosis Management Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 27: North America Cirrhosis Management Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 28: North America Cirrhosis Management Market Value (US$ Mn) Analysis by Treatment, 2016-2032

Figure 29: North America Cirrhosis Management Market Value Share (%) and BPS Analysis by Treatment, 2022-2032

Figure 30: North America Cirrhosis Management Market Y-o-Y Growth (%) Projections by Treatment, 2022-2032

Figure 31: North America Cirrhosis Management Market Value (US$ Mn) Analysis by Disease Indication, 2016-2032

Figure 32: North America Cirrhosis Management Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032

Figure 33: North America Cirrhosis Management Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032

Figure 34: North America Cirrhosis Management Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 35: North America Cirrhosis Management Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 36: North America Cirrhosis Management Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 37: North America Cirrhosis Management Market Attractiveness by Treatment, 2022-2032

Figure 38: North America Cirrhosis Management Market Attractiveness by Disease Indication, 2022-2032

Figure 39: North America Cirrhosis Management Market Attractiveness by End User, 2022-2032

Figure 40: North America Cirrhosis Management Market Attractiveness by Country, 2022-2032

Figure 41: Latin America Cirrhosis Management Market Value (US$ Mn) by Treatment, 2022-2032

Figure 42: Latin America Cirrhosis Management Market Value (US$ Mn) by Disease Indication, 2022-2032

Figure 43: Latin America Cirrhosis Management Market Value (US$ Mn) by End User, 2022-2032

Figure 44: Latin America Cirrhosis Management Market Value (US$ Mn) by Country, 2022-2032

Figure 45: Latin America Cirrhosis Management Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 46: Latin America Cirrhosis Management Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 47: Latin America Cirrhosis Management Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 48: Latin America Cirrhosis Management Market Value (US$ Mn) Analysis by Treatment, 2016-2032

Figure 49: Latin America Cirrhosis Management Market Value Share (%) and BPS Analysis by Treatment, 2022-2032

Figure 50: Latin America Cirrhosis Management Market Y-o-Y Growth (%) Projections by Treatment, 2022-2032

Figure 51: Latin America Cirrhosis Management Market Value (US$ Mn) Analysis by Disease Indication, 2016-2032

Figure 52: Latin America Cirrhosis Management Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032

Figure 53: Latin America Cirrhosis Management Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032

Figure 54: Latin America Cirrhosis Management Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 55: Latin America Cirrhosis Management Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 56: Latin America Cirrhosis Management Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 57: Latin America Cirrhosis Management Market Attractiveness by Treatment, 2022-2032

Figure 58: Latin America Cirrhosis Management Market Attractiveness by Disease Indication, 2022-2032

Figure 59: Latin America Cirrhosis Management Market Attractiveness by End User, 2022-2032

Figure 60: Latin America Cirrhosis Management Market Attractiveness by Country, 2022-2032

Figure 61: Europe Cirrhosis Management Market Value (US$ Mn) by Treatment, 2022-2032

Figure 62: Europe Cirrhosis Management Market Value (US$ Mn) by Disease Indication, 2022-2032

Figure 63: Europe Cirrhosis Management Market Value (US$ Mn) by End User, 2022-2032

Figure 64: Europe Cirrhosis Management Market Value (US$ Mn) by Country, 2022-2032

Figure 65: Europe Cirrhosis Management Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 66: Europe Cirrhosis Management Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 67: Europe Cirrhosis Management Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 68: Europe Cirrhosis Management Market Value (US$ Mn) Analysis by Treatment, 2016-2032

Figure 69: Europe Cirrhosis Management Market Value Share (%) and BPS Analysis by Treatment, 2022-2032

Figure 70: Europe Cirrhosis Management Market Y-o-Y Growth (%) Projections by Treatment, 2022-2032

Figure 71: Europe Cirrhosis Management Market Value (US$ Mn) Analysis by Disease Indication, 2016-2032

Figure 72: Europe Cirrhosis Management Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032

Figure 73: Europe Cirrhosis Management Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032

Figure 74: Europe Cirrhosis Management Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 75: Europe Cirrhosis Management Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 76: Europe Cirrhosis Management Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 77: Europe Cirrhosis Management Market Attractiveness by Treatment, 2022-2032

Figure 78: Europe Cirrhosis Management Market Attractiveness by Disease Indication, 2022-2032

Figure 79: Europe Cirrhosis Management Market Attractiveness by End User, 2022-2032

Figure 80: Europe Cirrhosis Management Market Attractiveness by Country, 2022-2032

Figure 81: Asia Pacific Cirrhosis Management Market Value (US$ Mn) by Treatment, 2022-2032

Figure 82: Asia Pacific Cirrhosis Management Market Value (US$ Mn) by Disease Indication, 2022-2032

Figure 83: Asia Pacific Cirrhosis Management Market Value (US$ Mn) by End User, 2022-2032

Figure 84: Asia Pacific Cirrhosis Management Market Value (US$ Mn) by Country, 2022-2032

Figure 85: Asia Pacific Cirrhosis Management Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 86: Asia Pacific Cirrhosis Management Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 87: Asia Pacific Cirrhosis Management Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 88: Asia Pacific Cirrhosis Management Market Value (US$ Mn) Analysis by Treatment, 2016-2032

Figure 89: Asia Pacific Cirrhosis Management Market Value Share (%) and BPS Analysis by Treatment, 2022-2032

Figure 90: Asia Pacific Cirrhosis Management Market Y-o-Y Growth (%) Projections by Treatment, 2022-2032

Figure 91: Asia Pacific Cirrhosis Management Market Value (US$ Mn) Analysis by Disease Indication, 2016-2032

Figure 92: Asia Pacific Cirrhosis Management Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032

Figure 93: Asia Pacific Cirrhosis Management Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032

Figure 94: Asia Pacific Cirrhosis Management Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 95: Asia Pacific Cirrhosis Management Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 96: Asia Pacific Cirrhosis Management Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 97: Asia Pacific Cirrhosis Management Market Attractiveness by Treatment, 2022-2032

Figure 98: Asia Pacific Cirrhosis Management Market Attractiveness by Disease Indication, 2022-2032

Figure 99: Asia Pacific Cirrhosis Management Market Attractiveness by End User, 2022-2032

Figure 100: Asia Pacific Cirrhosis Management Market Attractiveness by Country, 2022-2032

Figure 101: MEA Cirrhosis Management Market Value (US$ Mn) by Treatment, 2022-2032

Figure 102: MEA Cirrhosis Management Market Value (US$ Mn) by Disease Indication, 2022-2032

Figure 103: MEA Cirrhosis Management Market Value (US$ Mn) by End User, 2022-2032

Figure 104: MEA Cirrhosis Management Market Value (US$ Mn) by Country, 2022-2032

Figure 105: MEA Cirrhosis Management Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 106: MEA Cirrhosis Management Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 107: MEA Cirrhosis Management Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 108: MEA Cirrhosis Management Market Value (US$ Mn) Analysis by Treatment, 2016-2032

Figure 109: MEA Cirrhosis Management Market Value Share (%) and BPS Analysis by Treatment, 2022-2032

Figure 110: MEA Cirrhosis Management Market Y-o-Y Growth (%) Projections by Treatment, 2022-2032

Figure 111: MEA Cirrhosis Management Market Value (US$ Mn) Analysis by Disease Indication, 2016-2032

Figure 112: MEA Cirrhosis Management Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032

Figure 113: MEA Cirrhosis Management Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032

Figure 114: MEA Cirrhosis Management Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 115: MEA Cirrhosis Management Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 116: MEA Cirrhosis Management Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 117: MEA Cirrhosis Management Market Attractiveness by Treatment, 2022-2032

Figure 118: MEA Cirrhosis Management Market Attractiveness by Disease Indication, 2022-2032

Figure 119: MEA Cirrhosis Management Market Attractiveness by End User, 2022-2032

Figure 120: MEA Cirrhosis Management Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Liver Fluke Treatment Market

Published : April 2019

Food and Beverage

Liver Health Supplements Market

Published : March 2019

Healthcare

Fatty Liver Treatment Market

Published : April 2016

Healthcare

Liver Transplantation Market

Published : March 2016

Google translate

Cirrhosis Management Market